Dosage and administration
Use in the morning after applying Tri-Phasic White Essence. Apply liberally to face and neck.
Use in the morning after applying Tri-Phasic White Essence. Apply liberally to face and neck.
Avobenzone (2.4%), Octinoxate (7.4%), Octisalate (3.0%).
For external use only.
Discontinue use if irritation occurs.
Use in the morning after applying Tri-Phasic White Essence. Apply liberally to face and neck.
Water (Aqua), Cyclomethicone, Butylene Glycol, Bis-PEG/PPG-16/16 PEG/PPG-16/16 Dimethicone, Octyldodecyl Neopentanoate, Glycerin, Squalane, Hexapeptide-2, Caprylic/Capric Triglyceride, Phenyl Trimethicone, Tocopheryl Acetate, Allantoin, Phospholipids, Xanthan Gum, Dimethiconol, Dextran, Polyphosphorylcholine Glycol Acrylate, Polysorbate 80, PEG-8, Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Polysorbate 60, Aminomethyl Propanol, Disodium EDTA, Fragrance (Parfum), Phenoxyethanol, Chlorphenesin, Methylparaben, Benzoic Acid.
1-888-742-7626
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 62839-0273-1 | 2025-01-30 | C162847 | 48780-1 | c7ccaba7-24b4-fd44-e053-dadaa90aa01b | NU SKIN Tri-Phasic White ® |
| 62839-0273-1 | 2022-12-20 | C162847 | 48780-1 | c7ccaba7-24b4-fd44-e053-dadaa90aa01b | NU SKIN Tri-Phasic White ® |
| 62839-0273-1 | 2021-07-23 | C162847 | 48780-1 | c7ccaba7-24b4-fd44-e053-dadaa90aa01b | NU SKIN Tri-Phasic White ® |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 62839-0273 | NU SKIN TRI-PHASIC WHITE DAY MILK BROAD SPECTRUM SPF 15 (AVOBENZONE, OCTINOXATE, AND OCTISALATE) LOTION [NSE PRODUCTS, INC.] | 4 | Legacy NDC | 20221222_9e104ad0-088a-47ee-a037-3c9fa3af797c.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Avobenzone | ACTIVE INGREDIENT | G63QQF2NOX | 2 | |
| Octinoxate | ACTIVE INGREDIENT | 4Y5P7MUD51 | 2 | |
| Octisalate | ACTIVE INGREDIENT | 4X49Y0596W | 2 | |
| Avobenzone | ACTIVE MOIETY | G63QQF2NOX | 2 | |
| Octinoxate | ACTIVE MOIETY | 4Y5P7MUD51 | 2 | |
| Octisalate | ACTIVE MOIETY | 4X49Y0596W | 2 | |
| Allantoin | INACTIVE INGREDIENT | 344S277G0Z | 2 | |
| Aminomethylpropanol | INACTIVE INGREDIENT | LU49E6626Q | 2 | |
| Benzoic Acid | INACTIVE INGREDIENT | 8SKN0B0MIM | 2 | |
| Butylene Glycol | INACTIVE INGREDIENT | 3XUS85K0RA | 2 | |
| Chlorphenesin | INACTIVE INGREDIENT | I670DAL4SZ | 2 | |
| Cyclomethicone | INACTIVE INGREDIENT | NMQ347994Z | 2 | |
| Edetate Disodium | INACTIVE INGREDIENT | 7FLD91C86K | 2 | |
| Glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 2 | |
| Medium-Chain Triglycerides | INACTIVE INGREDIENT | C9H2L21V7U | 2 | |
| Methylparaben | INACTIVE INGREDIENT | A2I8C7HI9T | 2 | |
| Octyldodecyl Neopentanoate | INACTIVE INGREDIENT | X8725R883T | 2 | |
| Phenoxyethanol | INACTIVE INGREDIENT | HIE492ZZ3T | 2 | |
| Phenyl Trimethicone | INACTIVE INGREDIENT | DR0K5NOJ4R | 2 | |
| POLYETHYLENE GLYCOL 400 | INACTIVE INGREDIENT | B697894SGQ | 2 | |
| Polysorbate 60 | INACTIVE INGREDIENT | CAL22UVI4M | 2 | |
| Polysorbate 80 | INACTIVE INGREDIENT | 6OZP39ZG8H | 2 | |
| Squalane | INACTIVE INGREDIENT | GW89575KF9 | 2 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 2 | |
| Xanthan Gum | INACTIVE INGREDIENT | TTV12P4NEE | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 62839-0273 | 62839-0273-1 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION/ DROPS / OPHTHALMIC | 1 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 225 mg | ||
| Methylparaben | METHYLPARABEN | A2I8C7HI9T | SOLUTION / RECTAL | 0.13 %w/v | ||
| Xanthan Gum | XANTHAN GUM | TTV12P4NEE | LOTION / TOPICAL | 0.3 %w/v | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | JELLY / TOPICAL | NA | ||
| Polysorbate 60 | POLYSORBATE 60 | CAL22UVI4M | OINTMENT / TOPICAL | 2 %w/w | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | CREAM, AUGMENTED / TOPICAL | 2 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SOLUTION / RECTAL | 315 mg | ||
| Butylene Glycol | BUTYLENE GLYCOL | 3XUS85K0RA | SYSTEM / TRANSDERMAL | 8.12 mg | ||
| Methylparaben | METHYLPARABEN | A2I8C7HI9T | TABLET, EXTENDED RELEASE / ORAL | 0.17 mg | ||
| Methylparaben | METHYLPARABEN | A2I8C7HI9T | SOLUTION / IRRIGATION | 2 %w/v | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | ELIXIR / ORAL | 1.3 mg/5ml | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SYRUP / ORAL | 40 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / TRANSDERMAL | 306.2 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRAMUSCULAR | 10 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, EXTENDED RELEASE / ORAL | 10 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | INJECTION / INTRAMUSCULAR | 406 mg | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | CREAM / TOPICAL | 6 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | TABLET, EFFERVESCENT / ORAL | 32 mg | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | SOLUTION / TOPICAL | 0.1 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / TOPICAL | 1971 mg | ||
| Medium-Chain Triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | SOLUTION / ORAL | 5566 mg | ||
| Benzoic Acid | BENZOIC ACID | 8SKN0B0MIM | GEL / TOPICAL | 0.1 %w/w | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION / AURICULAR (OTIC) | 0.01 %w/v | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | SOLUTION, CONCENTRATE / ORAL | 2813 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRALESIONAL | 0.05 %w/v | ||
| Medium-Chain Triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | CREAM / TOPICAL | 3300 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAVENOUS | 15 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / INTRAMUSCULAR | 4 mg | ||
| Xanthan Gum | XANTHAN GUM | TTV12P4NEE | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 2350 mg | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | TABLET, FILM COATED / ORAL | 20 mg | ||
| Xanthan Gum | XANTHAN GUM | TTV12P4NEE | TABLET / ORAL | 56 mg | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | INJECTION, SOLUTION / INTRAMUSCULAR | 20.3 %w/v | ||
| Methylparaben | METHYLPARABEN | A2I8C7HI9T | GEL / VAGINAL | 8 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION / INTRASYNOVIAL | 0.2 %w/v | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | OINTMENT / TOPICAL | 1950 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SOLUTION / OPHTHALMIC | 8 mg | ||
| Xanthan Gum | XANTHAN GUM | TTV12P4NEE | POWDER / ORAL | 275 mg | ||
| Methylparaben | METHYLPARABEN | A2I8C7HI9T | INJECTION / INTRAVENOUS | 95 mg | ||
| Medium-Chain Triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | SPRAY / TOPICAL | 540 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | TABLET, ORALLY DISINTEGRATING / ORAL | 3 mg | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | TABLET / ORAL | 193 mg | ||
| Allantoin | ALLANTOIN | 344S277G0Z | GEL / TOPICAL | 8 mg | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / SUBCUTANEOUS | 15 %w/v | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / RESPIRATORY (INHALATION) | 1 mg | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | TABLET, EXTENDED RELEASE / ORAL | 60 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / INTRAVENOUS | 0.05 %w/v | ||
| Methylparaben | METHYLPARABEN | A2I8C7HI9T | OINTMENT / OPHTHALMIC | 0.05 %w/w | ||
| Glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION / AURICULAR (OTIC) | 0.05 %w/w | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET / SUBLINGUAL | 0.08 mg | ||
| Methylparaben | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / INTRAVENOUS | 45 mg | ||
| Polysorbate 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, CHEWABLE / ORAL | 84 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SOLUTION / INTRAMUSCULAR | 4 mg | ||
| Medium-Chain Triglycerides | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | OINTMENT / TOPICAL | 20 %w/w | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | LIQUID / ORAL | 0.5 mg/1ml | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | CAPSULE / ORAL | 5 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION/ DROPS / AURICULAR (OTIC) | 0.01 %w/v | ||
| Xanthan Gum | XANTHAN GUM | TTV12P4NEE | SUSPENSION / TOPICAL | 0.11 %w/v |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| fe72b5a8-044a-432b-96d4-4ef82f2a6e22 | 9e104ad0-088a-47ee-a037-3c9fa3af797c | 2026-04-01 | Warnings | 9e104ad0-088a-47ee-a037-3c9fa3af797c |
Adverse event summaries are temporarily unavailable. Other product information remains available.